| Literature DB >> 33677614 |
Céline S Moret1, Edna Iordache1, Riccardo D'Ambrosi2, Michael T Hirschmann3.
Abstract
PURPOSE: There are contentious data about the role calcium pyrophosphate (CPP) crystals and chondrocalcinosis (CC) play in the progression of osteoarthritis (OA), as well as in the outcomes after knee arthroplasty. Hence, the purpose of this systematic review was to analyse the clinical and functional outcome, progression of OA and prosthesis survivorship after unicompartmental knee arthroplasty (UKA) and total knee arthroplasty (TKA) in patients with CC compared to patients without CC.Entities:
Keywords: Calcium pyrophosphate dihydrate; Chondrocalcinosis; Implant survival; Outcome; Total knee arthroplasty; Unicompartmental knee arthroplasty
Mesh:
Year: 2021 PMID: 33677614 PMCID: PMC8901495 DOI: 10.1007/s00167-021-06519-6
Source DB: PubMed Journal: Knee Surg Sports Traumatol Arthrosc ISSN: 0942-2056 Impact factor: 4.342
Fig. 1Prisma flow diagram showing the study selection process
Characteristics of included studies
| Authors | Woods (1995) | Pandit (2011) | Hernigou (2012) | Pandit (2016) | Hamilton (2017) | Kumar (2017) | Lee (2014) | Willems (2019) |
|---|---|---|---|---|---|---|---|---|
| Country | UK | UK | F | UK | UK | UK | USA | NL |
| Level of evidence | IV | IV | II | III | IV | III | III | III |
| Type of arthroplasty | Mobile bearing UKA | Mobile bearing UKA | Fixed bearing UKA | Mobile bearing UKA | Mobile bearing UKA | Mobile bearing UKA | TKA | TKA |
| Number of knees | 98 | 1000 | 234 | 78 | 1000 | 369 | 1500 | 408 |
| Female Pt. (%) | n/a | 52 | 51.45 | 47.1 | 52 | 41 | 64.6 | 66 |
| Age at surgery—mean (range or SD) y | 69a (50–79) | 66 (32–88) | 70b (60–89) | 68.8a (48–81) (8.3) | 66 (32–88) | 69.8 (8.7) | 70 (34–100) | 68.4 (9.5) |
| Follow-up time—mean (range or SD) y | 3.5a (0.33–8) | 6.4 (2.9) (min. 10 for 86 Pt.) | 10 (3.4) (min. 10 for 112 Pt.) | n/a | 10.3 (5.3–16.6) (min. 10 for 516 Pt.) | 10 (2.9) | 4.75 (2–10) | 5 (4.75–7) |
| Prevalence of CC at surgery (%) | 20.4 | 12.6 | 36 (63c) | n/a | 13 | 15.2 | 26.4 | 15.4 |
| Diagnostic methods | Histology | Radiology and/or histology | Radiology and SF analysis | Histology | Radiology and/or histology | Radiology and histology | Visual | Radiology |
Pt. patients, SD standard deviation, y years, CC chondrocalcinosis, UK United Kingdom, F France, USA United States of America, NL The Netherlands, UKA unicompartemental arthroplasty, TKA total knee arthroplasty, n/a not available, min. minimum, SF synovial fluid
aOnly case group
bMedian
cIncluding patients that developed CC during follow-up
Clinical and functional outcomes (scores) at last follow-up
| Authors | Woods (1995) | Pandit (2011) | Hernigou (2012) | Pandit (2016) | Hamilton (2017) | Kumar (2017) | Lee (2014) | Willems (2019) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | CC | N-CC | CC | N-CC | CC | N-CC | OARev | N-Rev | CC | N-CC | 1 2 3 | CC H-CC R-CC | N-CC N-CC N-CC | CC | N-CC | CC | N-CC | |
| OKS (mean, SD) | n/a | n/a | n/a | 1 | 43 (7) | 41 (8) | n/a | |||||||||||
| n.s | ||||||||||||||||||
| 42.4 (7.0) | 40.9 (7.8) | 39.9 (10) | 39.7 (8) | 2 | 44 (6) | 41 (8) | 11.4 (8.9) | 14.3 (10.0) | ||||||||||
| n.s | n.s | |||||||||||||||||
| 3 | 42 (8) | 41 (8) | ||||||||||||||||
| n.s | ||||||||||||||||||
| Delta OKS | n/a | n/a | n/a | n/a | n/a | 1 | 19 (10) | 15 (10) | n/a | n/a | ||||||||
| 2 | 21(9) | 15 (10) | ||||||||||||||||
| 3 | 18 (10) | 15 (10) | ||||||||||||||||
| n.s | ||||||||||||||||||
| KSS (mean, SD or range) | n/a | n/a | 174 (85–196) | 178 (110– 200) | n/a | n/a | n/a | n/a | n/a | |||||||||
| KSS-KS | n/a | 87.1 (11.) | 84.5 (11.5) | n/a | n/a | 79.8 (15) | 80.4 (15) | n/a | 93 (95% CI, 87–97) | 94 (95% CI, 87–95) | 21.7 (22.3) | 18.7 (26.0) | ||||||
| n.s | ||||||||||||||||||
| KSS-KF | n/a | 83.0 (17.7) | 83.5 (20.1) | n/a | n/a | 73.7 (23) | 76.4 (22) | n/a | 68 (57–81) | 68 (59–75) | 14.5 (37.4) | 15.8 (33.0) | ||||||
| n.s | ||||||||||||||||||
| TAS (mean, SD) | n/a | 2.9 (1.3) | 2.8 (1.2) | n/a | n/a | 2.5 (1) | 2.5 (1) | n/a | n/a | n/a | ||||||||
| ROM (mean, 95% CI) ° | n/a | n/a | n/a | n/a | n/a | n/a | 113 (95–117) | 112 ( 89–119) | n/a | |||||||||
| Pain (%) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |||||||||||
| None to mild at rest | 95 | 91 | ||||||||||||||||
| n.s | ||||||||||||||||||
| Moderate to severe at rest | 5 | 9 | ||||||||||||||||
| n.s | ||||||||||||||||||
| None to mild walking | 95 | 88 | ||||||||||||||||
| n.s | ||||||||||||||||||
| Moderate to severe walking | 5 | 12 | ||||||||||||||||
| n.s | ||||||||||||||||||
| AODL | n/a | n/a | n/a | n/a | n/a | n/a | ||||||||||||
| Cooking | n/a | |||||||||||||||||
| Rising | ||||||||||||||||||
| Using restrooms | ||||||||||||||||||
| Going upstairs | ||||||||||||||||||
| Going shopping | ||||||||||||||||||
| AFI (mean, SD) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | − 6.2 (5.1) | − 6.7 (4.9) | |||||||||
| n.s | ||||||||||||||||||
OKS Oxford Knee Score, KSS Knee Society Score, KSS-KS Knee Society Score-knee score, KSS-KF Knee Society Score-knee function, TAS Tegner Activity Scale, ROM range of motion, AODL activities of daily living, AFI algofunctional index, SD standard deviation, CI confidence interval, CC chondrocalcinosis, N-CC no chondrocalcinosis, OARev revision surgery for osteoarthritis progression, N-Rev no revision for osteoarthritis progression, H-CC histological chondrocalcinosis, R-CC radiological chondrocalcinosis, n/a not available, n.s. not significant, HR hazard ratio
Prosthesis survivorship
| Authors | Woods (1995) | Pandit (2011) | Hernigou (2012) | Pandit (2016) | Hamilton (2017) | Kumar (2017) | Lee (2014) | Willems (2019) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | CC | N-CC | CC | N-CC | CC | N-CC | OARev | N-Rev | CC | N-CC | 1 2 3 | CC H-CC R-CC | N-CC N-CC N-CC | CC | N-CC | CC | N-CC |
| Revision rate at last FU (%) | 5 | 10 | 3.2 | 2.9 | n/a | n/a | n/a | n/a | 3.6 | 2.2 | 2 | 5 | |||||
| n.s | n.s | ||||||||||||||||
| 10 year survival rate (%) (95% CI) | n/a | n/a | n/a | n/a | 1 | 91.8 (82.6–96.2) | 98.3 (94.3–99.5) | n/a | n/a | ||||||||
| HR 3.3 (1.0–11.7) | |||||||||||||||||
| n.s | |||||||||||||||||
| 95.4 (91.4–99.4) | 2 | 86.1 (69.6–94.0 | 99.2 (94.7–99.9) | ||||||||||||||
| HR 5.8 (1.2–28.3) | |||||||||||||||||
| 3 | 96.3 (92.4–99.6) | 98.2 (92.4–99.9) | |||||||||||||||
| HR 2.9 (0.5–18.1) | |||||||||||||||||
| n.s | |||||||||||||||||
| 15 year survival rate (%) (95% CI) | n/a | n/a | 87 | 90 | n/a | 91.6 (76.9–100) | 92.3 (86.3–98.4) | n/a | n/a | n/a | |||||||
| Time to revision surgery—mean (range) m | 13 (7–19) | 71 (24–91) | 24 (9.6–67.2) | 40.8 (2.4–120) | n/a | n/a | n/a | n/a | 50 (31–98) | 46 (28–113) | n/a | ||||||
| n.s | n.s | p = 0.12 | p = 0.68 | ||||||||||||||
FU follow-up, CI confidence interval, m months, CC chondrocalcinosis, N-CC no chondrocalcinosis, OARev revision surgery for osteoarthritis progression, N-Rev no revision for osteoarthritis progression, H-CC histological chondrocalcinosis, R-CC radiological chondrocalcinosis, n.s. not significant, n/a not available, HR hazard ratio